<DOC>
	<DOCNO>NCT00463086</DOCNO>
	<brief_summary>The purpose study evaluate whether isoniazid safely ( ) reduce risk tuberculosis HIV infect people receive HAART .</brief_summary>
	<brief_title>Isoniazid Plus Antiretroviral Therapy Prevent Tuberculosis HIV-infected Persons</brief_title>
	<detailed_description>The incidence Tuberculosis ( TB ) poor settlement around Cape Town continue rise despite highly-active-anti-retroviral therapy ( HAART ) roll-out DOTS . In Khayelitsha district , project conduct , TB incidence 1600/100000 . There equally high HIV prevalence , currently 33 % . Over 50 % adult present active TB co-infected HIV third patient start HAART active TB . Although HAART show reduce overall risk TB 59-80 % , risk still far exceed general risk . In Khayelitsha HAART cohort , risk develop TB whilst HAART ~12 per 100 p-y . In nearby community Gugulethu , 14 % risk active TB least half case occur within first 3months HAART . In region RD1-detected prevalence latent TB infection least 80 % , real concern TB likely undo benefit HAART long run . Additional measure therefore require reduce risk TB already receive start HAART . Isoniazid preventive therapy ( IPT ) represent option insufficient evidence determine whether IPT ( safely ) reduce risk TB HAART era . In RCT , propose evaluate whether IPT reduce risk active TB patient receive HAART . A total minimum sample size 1204 require study detect 35 % reduction hazard rate tuberculosis intervention group ( h1= 0.052 ) compare control group ( h0=0.085 ) power 80 % Type II error 0.05 . Our maximum target sample size loss follow-up subgroup analysis consider 1445 . Development TB primary endpoint . Additional information ( 10 August 2010 ) : Recruitment enrolment study complete October 2009 . We screen 2000 patient already ART newly start ART . However , instead enrol desire maximum sample size 1445 , revise minimum total 1368 instead randomize study drug . This follow amendment sample size necessitate new information clinical site ; primarily high rate patient lose follow-up clinical site previously anticipate . The amendment sample size report , acknowledge , Research Ethics Committee University Cape Town . Follow-up participant continue Oct/November 2011 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Latent Tuberculosis</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<criteria>1 . Male female attendee ( age â‰¥18yo ) Ubuntu HIV ARV Clinic identify eligible ARV programme invite participate . 2 . Willingness participate 3 . Able engage inform consent procedure 1 . Evidence active TB suspicion active TB determine symptom screen algorithm . 2 . Current TB chemotherapy ( TB treatment complete precede 30 day exclusion ) 3 . Current previous treatment latent TB infection since HIV infection ( duration ) 4 . Current treatment fluoroquinolones antibiotic significant antituberculous activity currently use treat TB South Africa 5 . Past reaction/intolerance INH . 6 . Acute hepatitis exist Grade IIIIV peripheral neuropathy . 7 . Pregnancy &lt; 6weeks postpartum period ( Due increase risk hepatotoxicity ) . 8 . Grade III high baseline abnormal liver function . ( Note : toxicity grade accord ACTG toxicity table person ART ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>TB</keyword>
	<keyword>Mycobacteria</keyword>
	<keyword>HIV</keyword>
	<keyword>Human immunodeficiency virus</keyword>
	<keyword>Latent tuberculosis infection</keyword>
	<keyword>HAART</keyword>
	<keyword>Highly active anti-retroviral therapy</keyword>
	<keyword>Isoniazid preventive therapy</keyword>
	<keyword>INH</keyword>
	<keyword>Opportunistic infection</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>AIDS</keyword>
	<keyword>Mycobacterium Tuberculosis</keyword>
</DOC>